Unum Therapeutics Inc (UMRX) Receives Consensus Rating of “Buy” from Analysts

Shares of Unum Therapeutics Inc (NASDAQ:UMRX) have earned a consensus recommendation of “Buy” from the six analysts that are currently covering the firm, Marketbeat.com reports. One investment analyst has rated the stock with a hold rating and five have issued a buy rating on the company. The average 12-month price target among brokerages that have updated their coverage on the stock in the last year is $14.60.

UMRX has been the subject of several recent research reports. Cowen initiated coverage on shares of Unum Therapeutics in a research note on Tuesday, February 26th. They set a “market perform” rating for the company. HC Wainwright reiterated a “buy” rating and set a $18.00 target price on shares of Unum Therapeutics in a research note on Tuesday, May 14th. Zacks Investment Research lowered shares of Unum Therapeutics from a “buy” rating to a “hold” rating in a research note on Thursday, February 21st. Finally, SunTrust Banks lowered their target price on shares of Unum Therapeutics to $10.00 and set a “buy” rating for the company in a research note on Friday, March 29th. They noted that the move was a valuation call.

Shares of NASDAQ:UMRX opened at $3.38 on Friday. The company has a debt-to-equity ratio of 0.11, a current ratio of 2.65 and a quick ratio of 3.25. The firm has a market capitalization of $103.91 million, a P/E ratio of -2.43 and a beta of 2.25. Unum Therapeutics has a 12-month low of $3.03 and a 12-month high of $17.66.

Unum Therapeutics (NASDAQ:UMRX) last released its earnings results on Monday, May 13th. The company reported ($0.39) earnings per share for the quarter, missing the consensus estimate of ($0.31) by ($0.08). Unum Therapeutics had a negative net margin of 373.81% and a negative return on equity of 62.24%. The business had revenue of $3.05 million for the quarter, compared to the consensus estimate of $3.15 million. Equities research analysts predict that Unum Therapeutics will post -1.35 earnings per share for the current year.

In other Unum Therapeutics news, insider Seth Ettenberg sold 11,485 shares of the business’s stock in a transaction on Monday, March 25th. The shares were sold at an average price of $4.12, for a total transaction of $47,318.20. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink.

A number of hedge funds have recently added to or reduced their stakes in UMRX. American International Group Inc. increased its stake in Unum Therapeutics by 432.8% during the fourth quarter. American International Group Inc. now owns 12,531 shares of the company’s stock valued at $55,000 after purchasing an additional 10,179 shares during the last quarter. Parametric Portfolio Associates LLC bought a new position in shares of Unum Therapeutics during the first quarter worth about $61,000. Acadian Asset Management LLC bought a new position in shares of Unum Therapeutics during the first quarter worth about $61,000. Rhumbline Advisers bought a new position in shares of Unum Therapeutics during the first quarter worth about $85,000. Finally, State of Wisconsin Investment Board bought a new position in shares of Unum Therapeutics during the first quarter worth about $114,000. Hedge funds and other institutional investors own 47.35% of the company’s stock.

Unum Therapeutics Company Profile

Unum Therapeutics Inc, a clinical stage biopharmaceutical company, develops and commercializes immunotherapy products designed to harness the power of a patient's immune system to cure cancer. The company's lead product candidate is the ACTR707 used in combination with rituximab, which is in Phase I clinical trials to treat adult patients with relapsed or refractory CD20+ B cell non-Hodgkin lymphoma (r/r NHL).

Featured Article: What is Considered a Good Return on Equity (ROE)?

Analyst Recommendations for Unum Therapeutics (NASDAQ:UMRX)

Receive News & Ratings for Unum Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Unum Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.